Why Novo Nordisk Shares Fell and What the Turnaround Now Depends On
Investors have knocked Novo Nordisk shares down sharply after a capital markets day in London left them cold. This article explains the reasons for the slide and the conditions the Danish drugmaker must meet to turn its stock around.
Novo Nordisk started the trading week down about 5 percent, then fell as much as 9 percent during the session. The trigger was a capital markets day in London that failed to reassure investors. According to Wallstreet Online, analysts came away questioning the Danish drugmaker's pricing power and its acquisition strategy. The stock remains more than 70 percent below its record high, a stark contrast with US rival Eli Lilly, whose shares have risen strongly in the same period.
The Patent Clock Is the Problem
The core worry is not hard to find: patents on semaglutide, the active ingredient in Wegovy and Ozempic, begin to expire in the early 2030s. That gives Novo a limited window to defend its position in obesity and diabetes treatments. The company's answer, laid out at the London event, is a plan to bring more than five blockbusters to market by 2030 and to generate pipeline revenues of over 150 billion Danish kroner, roughly 23 billion US dollars, by 2035.
There are also concrete production goals. Novo wants to reach more than 60 million patients worldwide by the end of the decade, and it plans to increase manufacturing of its weight-loss pills tenfold so that 15 million patients can be treated with oral obesity therapies. The Wegovy pill is already showing momentum in the United States, where it has recorded 7 million prescriptions, about 90 percent of them paid for directly by patients rather than insurers.
The Near-Term Outlook Is Flat
Investors looking for immediate reassurance did not get it. For fiscal 2026, revenue and profit are expected to stagnate at best, and adjusted operating earnings per share are likely to decline, according to Aktienwelt360. That leaves a clear gap: the company's growth story does not really start until 2027, and the market is waiting to see what closes the gap.
The pill market itself could help. Europe alone may offer a market potential of up to 6.7 billion US dollars for obesity pills by 2035, within a total obesity treatment market estimated at up to 33.6 billion US dollars. CagriSema, a potential successor to semaglutide, has not matched Eli Lilly's products head-to-head, so the pipeline needs to carry more weight.
What a Turnaround Would Take
At a price-to-earnings ratio of just above 10 and a dividend yield over 4 percent, the valuation already looks cheap. The dividend helps stabilize income investors, but Aktienwelt360 argues that a turnaround needs more. A large package of share buybacks right now would be the tool of choice, supported by stable and sensible capital returns. If management delivers that combination, the article concludes, a turnaround is very possible.
The stakes are high. Novo's next few years will show whether it can convert its production scale and pipeline ambitions into a real growth story before the patent clock runs out.